Arctigenin blocks the unfolded protein response and shows therapeutic antitumor activity

Journal of Cellular Physiology

Volumn 224, Issue 1, 2010, Pages 33-40

  Kim, Ju Young ^a,b   Hwang, Ji Hwan ^a,c   Cha, Mi Ran ^a   Yoon, Mi Young ^a   Son, Eun Soon ^a   Tomida, Akihiro ^d   Ko, Bosung ^e   Song, Si Whan ^e   Shin Ya, Kazuo ^c   Hwang, Yong Il ^a   Park, Hae Ryong ^a  

^a Kyungnam University   (South Korea)

^b Eulji University   (South Korea)

^c Japan Biological Information Research Center   (Japan)

^d CANCER CHEMOTHERAPY CENTER   (Japan)

^e Chemon Inc   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; ANTINEOPLASTIC AGENT; ARCTIGENIN; CASPASE 2; CASPASE 3; CASPASE 8; CASPASE 9; GLUCOSE; GLUCOSE REGULATED PROTEIN 78; INITIATION FACTOR 2ALPHA; TUMOR SUPPRESSOR PROTEIN; FURAN DERIVATIVE; LIGNAN;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL STRAIN HT29; CELL VIABILITY; COLON CANCER; CYTOTOXICITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REAL TIME POLYMERASE CHAIN REACTION; SCREENING; TUMOR CELL; TUMOR VOLUME; UNFOLDED PROTEIN RESPONSE; WESTERN BLOTTING; XENOGRAFT; ANIMAL; CELL SURVIVAL; COLON TUMOR; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HELA CELL; METABOLISM; NUDE MOUSE; PATHOLOGY; TIME;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL SURVIVAL; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FURANS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE; HELA CELLS; HT29 CELLS; HUMANS; LIGNANS; MICE; MICE, NUDE; TIME FACTORS; TUMOR BURDEN; UNFOLDED PROTEIN RESPONSE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77952502347     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22085     Document Type: Article

References (36)

1. Awale S, Lu J, Kalauni SK, Kurashima Y, Tezuka Y, Kadota S, Esumi H. 2006. Identification of arctigenin as an antitumor agent having the ability to eliminate the tolerance of cancer cells to nutrient starvation. Cancer Res 66:1751-1757. (Pubitemid 43259960)
2. Britten CD, Hilsenbeck SG, Eckhardt SG, Marty J, Mangold G, MacDonald JR, Rowinsky EK, Von Hoff DD, Weitman S. 1999. Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT-29 human colon tumor xenograft model. Cancer Res 59:1049-1053. (Pubitemid 29135965)
3. Brown JM, Giaccia AJ. 1998. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res 58:1408-1416.
4. Chen M, Wang J. 2002. Initiator caspases in apoptosis signaling pathways. Apoptosis 7:313-319.
5. Cho MK, Jang YP, Kim YC, Kim SG. 2004. Arctigenin, a phenylpropanoid dibenzylbutyrolactone lignan, inhibits MAP kinases and AP-1 activation via potent MKK inhibition: The role in TNF-a inhibition. Int Immunopharmacol 4:1419-1429.
6. Choi HJ, Yee SB, Park SE, Im E, Jung JH, Chung HY, Choi YH, Kim ND. 2006. Petrotetrayndiol A induces cell cycle arrest and apoptosis in SK-MEL-2 human melanoma cells through cytochrome c-mediated activation of caspases. Cancer Lett 232:214-225.
7. Decker T, Lohmann-Matthes ML. 1988. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Methods 115:61-69.
8. Decker P, Muller S. 2002. Modulating poly (ADP-ribose) polymerase activity: Potential for the prevention and therapy of pathogenic situations involving DNA damage and oxidative stress. Curr Pharm Biotechnol 3:275-283.
9. Fisher B. 1984. Clinical trials for the evaluation of cancer therapy. Cancer 54:2609-2617. (Pubitemid 15187398)
10. Harding HP, Novoa I, Zhang Y, Zeng H, Wek R, Schapira M, Ron D. 2000a. Regulated translation initiation controls stress-induced gene expression inmammalian cells. Mol Cell 6:1099-1108.
11. Harding HR, Zhang Y, Bertolotti A, Zeng H, Ron D. 2000b. Perk is essential for translational regulation and cell survival during the unfolded protein response. Mol Cell 5:897-904.
12. Harding HP, Calfon M, Urano F, Novoa I, Ron D. 2002. Transcriptional and translational control in the mammalian unfolded protein response. Annu Rev Cell Dev Biol 18:575-599.
13. Jang YP, Kim SR, Choi YH, Kim J, Kim SG, Markelonis GJ, Oh TH, Kim YC. 2002. Arctigenin protects cultured cortical neurons from glutamate-induced neurodegeneration by binding to kainate receptor. J Neurosci Res 68:233-240.
14. Jiang HY, Wek RC. 2005. Phosphorylation of the a-subunit of the eukaryotic initiation factor-2 (eIF2α) reduces protein synthesis and enhances apoptosis in response to proteasome inhibition. J Biol Chem 280:14189-14202.
15. Kaufman RJ. 1999. Stress signaling from the lumen of the endoplasmic reticulum: Coordination of gene transcriptional and translational controls. Genes Dev 13:1211-1233.
16. Kaufman RJ. 2002. Orchestrating the unfolded protein response in health and disease. J Clin Invest 110:1389-1398.
17. Kaufman RJ. 2004. Regulation of mRNA translation by protein folding in the endoplasmic reticulum. Trends Biochem Sci 29:152-158.
18. Lee AS. 1992. Mammalian stress response: Induction of the glucose regulated protein family. Curr Opin Cell Biol 4:267-273.
19. Lee AS. 2007. GRP78 induction in cancer: Therapeutic and prognostic implications. Cancer Res 67:3496-3499.
20. Lu J, Kunimoto S, Yamazaki Y, Kaminishi M, Esumi H. 2004. Kigamicin D, a novel anticancer agent based on a new anti-austerity strategy targeting cancer cells' tolerance to nutrient starvation. Cancer Sci 95:547-552.
21. Ma Y, Hendershot LM. 2001. The unfolding tale of the unfolded protein response. Cell 107:827-830.
22. Nadanaka S, Yoshida H, Kano F, Murata M, Mori K. 2004. Activation of mammalian unfolded protein response is compatible with the quality control system operating in the endoplasmic reticulum. Mol Biol Cell 15:2537-2548.
23. Novoa I, Zeng H, Harding HP, Ron D. 2001. Feedback inhibition of the unfolded protein response by GADD34-mediated dephosphorylation of eIF2a. J Cell Biol 153:1011-1021.
24. Ogiso Y, Tomida A, Lei S, Omura S, Tsuruo T. 2000. Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs. Cancer Res 60:2429-2434. (Pubitemid 30262433)
25. Ogiso Y, Tomida A, Tsuruo T. 2002. Nuclear localization of proteasomes participates in stress inducible resistance of solid tumor cells to topoisomerase II-directed drugs. Cancer Res 62:5008-5012. (Pubitemid 34984427)
26. Park HR, Tomida A, Sato S, Tsukumo Y, Yun J, Yamori T, Hayakawa Y, Tsuruo T, Shin-ya K. 2004. Effect of tumor cells of blocking survival response to glucose deprivation. J Natl Cancer Inst 96:1300-1310.
27. Park HR, Ryoo IJ, Choo SJ, Hwang JH, Kim JY, Cha MR, Shin-Ya K, Yoo ID. 2007. Glucose-deprived HT-29 human colon carcinoma cells are sensitive to verrucosidin as a GRP78 down-regulator. Toxicology 229:253-261.
28. Rao RV, Ellerby HM, Bredesen DE. 2004. Coupling endoplasmic reticulum stress to the cell death program. Cell Death Differ 11:372-380.
29. Suzuki H, Tomida A, Tsuruo T. 2001. Dephosphorylated hypoxia-inducible factor 1 alpha as a mediator of p53-dependent apoptosis during hypoxia. Oncogene 20:5779-5788.
30. Tomida A, Tsuruo T. 1999. Drug resistance mediated by cellular stress response to the microenvironment of solid tumors. Anticancer Drug Des 14:169-177. (Pubitemid 29292313)
31. Vaupel P. 2004. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 14:198-206.
32. Wek RC, Jiang HY, Anthony TG. 2006. Coping with stress: eIF2 kinases and translational control. Biochem Soc Trans 34:7-11.
33. Wolf BB, Schuler M, Echeverri F, Green DR. 1999. Caspase-3 is the primary activator of apoptotic DNA fragmentation via DNA fragmentation factor-45/inhibitor of caspase-activated DNase inactivation. J Biol Chem 274:30651-30656. (Pubitemid 129576806)
34. Yamori T, Matsunaga A, Sato S, Yamazaki K, Komi A, Ishizu K, Mita I, Edatsugi H, Matsuba Y, Takezawa K, Nakanishi O, Kohno H, Nakajima Y, Komatsu H, Andoh T, Tsuruo T. 1999. Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel. Cancer Res 59:4042-4049.
35. Yun J, Tomida A, Nagata K, Tsuruo T. 1995. Glucose-regulated stresses confer resistance to VP-16 in human cancer cells through a decreased expression of DNA topoisomerase II. Oncol Res 7:583-590. (Pubitemid 26107675)
36. Zhang K, Kaufman RJ. 2004. Signaling the unfolded protein response from the endoplasmic reticulum. J Biol Chem 25:25935-25938. (Pubitemid 38798732)